Saturday, 7th September, 2024
THE INNOVATION ISSUE
From Insight to Foresight Barcelona Congress to serve a veritable tablao of ophthalmic advancements.
PREVENT PATIENT’S VISION LOSS by EARLY
INTERVENE EARLY WITH THE ILINK™ V KXL 1B AND VIBEX ® RAPID CORNEAL CROSS-LINKING PLATFORM
SCREENING EARLY
DIAGNOSING EARLY
TREATMENT KXL® System
How iLink V™ helps to slow or halt the progression of keratoconus
PRESERVES Patient’s Vision
PROVEN and SAFE Treatment
IMPROVES Patient’s Quality of Life
May REDUCE or DELAY More Invasive Procedures
1- Three-Year Outcomes of Simultaneous Accelerated Corneal Crosslinking and Femto-LASIK for the Treatment of High Myopia in Asian Eyes. INDICATIONS: The KXL® System delivers a uniform, metered dose of UVA light to a targeted treatment area for the intended use of illuminating the cornea during corneal cross-linking procedures stabilising cornea which have been weakened by disease or by refractive surgery. VibeX® Rapid (riboflavin) are indicated for use in the treatment of corneal strengthening, progressive keratoconus, iatrogenic ectasia, pellucid marginal degeneration. ® 2024 Glaukos. iLink™ V is a registered trademark of Glaukos Corp. KXL® and VibeX® Rapid are registered trademarks of Avedro Inc., a Glaukos company.
AVEDRO, A GLAUKOS COMPANY